VAXXITEK® HVT+IBD provides long lasting protection against IBD and Marek’s disease which, demonstrated in field conditions, leads to better weight gain, feed conversion ratios, uniformity and more.1,8
Infectious Bursal Disease and Marek’s Disease are two major immunosuppressive diseases affecting poultry worldwide.

**Infectious Bursal Disease**

Infectious Bursal Disease (IBD) or Gumboro is a highly contagious viral infection in chickens. It is caused by serotype 1 IBD virus that destroys the lymphocytes in the bursa of Fabricius. This leads to immunosuppression and secondary infections.

Classical and vvIBD viruses are responsible for most cases of clinical IBD. The disease may appear suddenly and morbidity may reach 100%. Field infections may cause lethargy, muscle hemorrhage, bursitis, and mortality. Some classic and all variant IBD strains are associated with subclinical IBD, which may cause important economic losses due to immunosuppression and decreased performance. This disease occurs mainly, but not exclusively, in chickens under three weeks of age.

**Marek’s Disease**

Marek’s disease (MD) is a herpesvirus infection that can cause tumors and lesions due to the malignant transformation of the CD4+ lymphocytes. Clinical signs vary according to the affected tissue. Condemned carcasses and decreased egg production are common consequences. MD may be fatal.

Over the past decades, the MD virus has become increasingly virulent and immunosuppressive.

Infected birds become carriers and shedders of the virus.
VAXXITEK® HVT + IBD

WHAT IT IS
VAXXITEK® HVT+IBD offers simple, safe, single vaccination for long lasting protection against known classic, variant and very virulent IBDV strains and Marek’s disease.²

HOW IT WORKS
• One single vaccination to protect against IBD and MD
• Only one hatchery administration in one-day-old chicks or in ovo
• Broad protection against most pathotypes of the IBD virus
• Lifelong immunity in broilers: up to 10 weeks duration of immunity
• Early onset of immunity, no immunity gap³

MECHANISM OF ACTION

VAXXITEK® HVT+IBD starts to colonize targeted lymphocyte populations between one and two weeks of age. During replication, IBD viral VP2 protein is expressed. HVT and VP2 will induce an immune response that will protect chickens against both IBD and MD.²
Variant and classic strains of IBDV share common protective antigens, especially viral protein 2 (VP2).

The immunogenicity of the VP2 antigen is a key feature for obtaining broad protection.

The IBDV genome contains double stranded RNA. VP2 is responsible for the protective immune response.

Most of the amino acid changes between antigenically different IBDV are clustered in the hypervariable region of VP 2 which is the region that elicits neutralizing antibodies.

---

**Efficacy against a broad spectrum of IBDV strains**

---
**EARLY ONSET OF IMMUNITY**

**VAXXITEK® HVT+IBD** provides the advantages of safe, early protection against Marek’s disease and IBD, even in the presence of respective maternally-derived antibodies (MDA).²

**EARLY PROTECTION**

Early protection is needed to avoid the immunity gap,³ defined as the lack of protection between the decay of passive immunity from maternal antibodies and the rise of active immunity induced by vaccination.

**VAXXITEK® HVT+IBD** can be given at the hatchery to achieve early protection and avoid the immunity gap.³

**NO IMMUNITY GAP**

Immune protection against classic, variant and vvIBD has been demonstrated from 14 days of age.⁴

The onset of immunity against MD has been shown from 4 days of age.

---

**The immunity gap between waning of passive immunity and the onset of active immunity. During this period, birds are unprotected against IBD virus infection.**

---

**VAXXITEK® HVT+IBD** is administered to one-day-old chicks or in ovo, providing an early onset active immunity that is not neutralized by the maternal antibodies.
In addition to environmental factors, immunosuppression can be caused by stressors including viral diseases such as IBD and MD. Immunosuppression leads to poor disease resistance, increased treatment costs and mortality. Even in the absence of clinical signs, birds may show decreased performance, poor feed conversion and loss of carcass quality, all leading to economic loss.

Early vaccination against the main viral immunosuppressive diseases, Infectious Bursal Disease and Marek's disease, will lay the basis of the immune foundation.

**KEY BENEFITS**

- Viability
- Improved flock uniformity
- Economic benefits
- Increased daily weight
- Bursal protection
- Lower cost of meat production
- Decreased feed conversion
- Fewer carcass condemnations
- Decreased medication costs
- Decreased condemnation rates

**COMPATIBILITY**

**VACCINE COMPATIBILITIES/INCOMPATIBILITIES AT THE HATCHERY**

Approved for co-administration with Boehringer Ingelheim vaccines:

- SB-1 strain
- Rispens strain vaccines
- PREVEXXION™ RN
- ND and IB live vaccines (spray application)

Not approved for co-administration with:

Any HVT or vHVT vaccine, alone or in combination with other vaccines.
REFERENCES

1. Data on file at Boehringer Ingelheim.


10. Tang Shun Fa, He Shi Jun, Li Wan Meng & Lemiere Stephane. Field experience of vaccination at day-old of Broiler chickens with a Herpesvirus Turkey – Infectious Bursal Disease (HVT-IBD) vector vaccine in different systems of chicken production across China, Article. XVIIth Congress of the World Veterinary Poultry Association, Cancun, Mexico, 2011.


More than 65+ scientific papers published to date have shown that VAXXITEK® HVT+IBD provides long-lasting protection against IBD and MD in one single vaccination.
ONE INJECTION. MULTIPLE BENEFITS. PEACE OF MIND.

VAXXITEK® HVT+IBD provides protection for your flock against IBD and Marek’s disease backed by a trusted partner for service and support that helps move your business into the future.

PERFORMANCE BENEFITS & ROI
As demonstrated in field conditions, healthier birds lead to better weight gain, feed conversion ratios, uniformity and more.¹,⁸

CONVENIENCE & RELIABILITY
Just one shot in a controlled hatchery environment gives early, accurate, and consistent protection.²

BURSAL PROTECTION
VAXXITEK® HVT+IBD stimulates immunity without the damage to the bursa that can occur with conventional modified-live virus vaccines.³

PROVEN RESULTS
The numbers tell it all. Billions of birds have been protected with VAXXITEK® HVT+IBD worldwide.

LIFELONG IMMUNITY IN BROILERS
One single vaccine dose provides lifelong immunity—up to 10 weeks duration.²

BROAD PROTECTION
Highly effective protection in birds against several different strains of IBD including classical, variant and very virulent IBD (vvIBD) viruses.²

STRONG OVERALL IMMUNITY
The immune foundation of the birds is laid at the hatchery, allowing a tailor-made vaccination program according to the type of bird and the disease risk.⁶

BACKED BY SCIENCE
We support our vaccination services and poultry health programs with strong evidence: published research and trials conducted by Boehringer Ingelheim veterinary experts and field technicians.

Visit us at poultryhealthusa.com

VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. PREVEXXION™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. POU-0057-POUL0519